MOTS-c · 20mg
Research peptideMitochondrial peptide · activates AMPK · energy, metabolism and muscle
Overview
What has it been researched for?
- Improves insulin sensitivity Main focusEarly evidence
- More energy and physical performanceEarly evidence
- Reduces liver fatEarly evidence
- Preserves and protects muscleEarly evidence
- Stronger bonesEarly evidence
- Cellular longevity: sirtuins and repairEarly evidence
- Lowers body weightEarly evidence
Research protocols
The SBL research protocol and what the literature reports. Not medical advice.
SBL research protocol · no established clinical regimen in people
- Dose
- 2.5 mg
- Frequency
- 3×/semana · AM
- Duration
- 8 weeks
- Route
- Subcutaneous
- Evidence level
- Preclinical
Tools
Evidence and studies
See studies →Protocols
Research protocols
SBL research protocol · no established clinical regimen in people
Research use, with no established clinical regimen in people.
- Dose
- 2.5 mg
- Frequency
- 3×/semana · AM
- Timing
- mañana
- Duration
- 8 weeks
- Break
- 4 weeks
- Route
- Subcutaneous
- Evidence level
- Preclinical
Example dose
100-unit U-100 insulin syringe · Starting dose of its protocol, with 2 ml of water in the 20 mg vial.
What it pairs with
- Retatrutidepairs well
- Tirzepatidepairs well
- Tirzepatide Alongside a GLP-1 it preserves the muscle lost while losing weight.
- Retatrutide Alongside a GLP-1 it preserves the muscle lost while losing weight.
Preparation and dosing
Quick reference
Preparation
- Diluent
- Bacteriostatic water
Evidence
Each effect with its evidence level and, where available, its source.
- Improves insulin sensitivityPreclinicalSee study · 2015
- More energy and physical performancePreclinicalSee study · 2021
- Reduces liver fatPreclinicalSee study · 2024
- Preserves and protects musclePreclinicalSee study · 2021
- Stronger bonesPreclinicalSee study · 2016
- Cellular longevity: sirtuins and repairPreclinicalSee study · 2018
- Lowers body weightPreclinicalSee study · 2015
The science
Mechanisms, studies and references
Mitochondrial · AMPK
Safety
It makes sense if you want
- More energy & active metabolism
- Lose weight — most potent
- More muscle, strength & composition
It does not make sense if
- Active cancer or oncology treatment in the last 5 years
- Pregnancy or breastfeeding
Talk to your doctor first if this applies (7)
- Severe heart disease or recent cardiac event
- Type 2 diabetes / prediabetes
- GLP-1 (Ozempic, Wegovy, Mounjaro, Saxenda)
- Severe liver impairment
- Severe kidney impairment
- Insulin
- Sulfonylureas / metformin
The certificate of analysis (CoA) certifies the identity and purity of the batch. It does not certify safety of use.
Verify your batch →For research use only (RUO). This consult is educational and does not replace your doctor.
Questions
Frequently asked questions
What is it reconstituted with, and how much?
With bacteriostatic water: 2 ml into the 20 mg vial, giving 10 mg/ml.
What is the starting dose of the research protocol?
2.5 mg, 3×/semana · AM. This is the SBL research protocol, with no established clinical regimen in people.
How long is the cycle, and how long does a vial last?
8 weeks ON / 4 weeks OFF. At the starting dose, the 20 mg vial lasts ~2.7 sem.
Which route is used in research?
Subcutaneous.
When does it make no sense?
It makes no sense with: Active cancer or oncology treatment in the last 5 years, Pregnancy or breastfeeding. Details in the Safety tab.
What is it combined with?
It goes well with Retatrutide, Tirzepatide. The reasons are in the Protocols tab.
How do I check my batch?
With the code on the vial, in the verifier. The CoA certifies the identity and purity of the batch, not safety of use.
For research use only (RUO). This consult is educational and does not replace your doctor.